GALENA BIOPHARMA, INC. (NASDAQ:GALE) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
Entry Into A Material Definitive Agreement
|
Islands exempted company (the Investor) entered into a waiver
(the Waiver) that amended the Securities Purchase Agreement dated
May 10, 2016 between the Company and the Investor, as amended on
August 22, 2016 (the SPA). Under the terms of the SPA the Company
sold to the Investor a secured convertible debenture (the
Debenture), in the principal amount of $25,350,000. The Waiver
provides that solely with respect to the calendar months of April
2017, May 2017, June 2017, July 2017, August 2017 and September
2017 (collectively, the Specified Months), the Investor waives,
subject to certain delineated exceptions, the requirement of
paragraph (i) of the definition of Equity Conditions set forth in
Section 1 of the Debenture, thereby continuing to allow the
Company to deliver shares of its Common Stock in respect to a
portion of its amortization obligation under the Debenture. The
Waiver also continues the requirement that the cash and/or cash
equivalents in excess of remaining outstanding balance of the
Debenture be withdrawn from certain accounts and deposited into
an agreed to Company account and the Investor special redemptions
rights granted on December 14, 2016 as reported on the Current
Report on Form 8-K dated February 7, 2017.
qualified in their entirety by the Waiver, copies of which are
filed as Exhibit 10.1 on this Current Report on Form 8-K and are
incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits
|
10.1
|
Waiver dated April 1, 2017 to the Securities Purchase
Agreement, dated as of May 10, 2016 by and between Galena Biopharma Inc. and JGB Newton, Ltd. |
About GALENA BIOPHARMA, INC. (NASDAQ:GALE)
Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells. GALENA BIOPHARMA, INC. (NASDAQ:GALE) Recent Trading Information
GALENA BIOPHARMA, INC. (NASDAQ:GALE) closed its last trading session down -0.019 at 0.591 with 1,483,363 shares trading hands.